Source: http://www.google.com/patents/US7951614?dq=645576
Timestamp: 2013-12-05 17:41:33
Document Index: 601147388

Matched Legal Cases: ['Application No. 2004311630', 'Application No. 2004311630', 'Application No. 02729092', 'Application No. 02729092', 'art 1', 'art 1', 'Application No. 200480041234', 'Application No. 200480041234']

Patent US7951614 - Methods and compositions for the production of monoclonal antibodies - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Advanced Patent Search | Sign inAdvanced Patent SearchPatentsThe present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may...http://www.google.com/patents/US7951614?utm_source=gb-gplus-sharePatent US7951614 - Methods and compositions for the production of monoclonal antibodiesPublication numberUS7951614 B2Publication typeGrantApplication numberUS 12/549,207Publication dateMay 31, 2011Filing dateAug 27, 2009Priority dateDec 2, 2003Also published asCA2548179A1, CN1925843A, EP1694301A2, EP1694301A4, US8435801, US20050175583, US20100068261, US20110195456, WO2005065121A2, WO2005065121A3Publication number12549207, 549207, US 7951614 B2, US 7951614B2, US-B2-7951614, US7951614 B2, US7951614B2InventorsLawrence Tamarkin, Giulio F. PaciottiOriginal AssigneeCytimmune Sciences, Inc.Patent Citations (100), Non-Patent Citations (122), Referenced by (1), Classifications (37), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetMethods and compositions for the production of monoclonal antibodiesUS 7951614 B2Abstract The present invention comprises compositions and methods for making monoclonal antibodies. The present invention further comprises vectors that replicate the immune system components, particularly an antigen-presenting cell (APC) element of the immune synapse. Additionally, the present invention may further comprise synthetic T-cells.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2768958Apr 8, 1954Oct 30, 1956Goodrich Co B FColloidal dispersions of heavy metal compoundsUS2785153Sep 13, 1954Mar 12, 1957Crookes Barnes Lab IncSilver proteinUS3145144Sep 28, 1960Aug 18, 1964Takeda Pharmacentical Ind LtdProcess for manufacturing chromium treated vaccinesUS3149036Oct 16, 1961Sep 15, 1964Merck & Co IncAdjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agentUS3269912Apr 8, 1963Aug 30, 1966Boehringer & Soehne GmbhAluminum oxide depot vaccinesUS3399263Apr 12, 1965Aug 27, 1968American Cyanamid CoStable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acidUS3531565Sep 25, 1969Sep 29, 1970American Cyanamid CoStable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acidUS3577523Mar 7, 1969May 4, 1971Miles LabWater-insoluble antigenic substances and method of preparing the same and antigenic depot agents incorporating such substancesUS3651211Oct 16, 1967Mar 21, 1972Lockheed Aircraft CorpVirus inactivationUS3819820Sep 18, 1969Jun 25, 1974Aluisy RIrradiated substance and compound and method of preparing the sameUS3919413Nov 29, 1974Nov 11, 1975Univ NebraskaVaccine for neonatal calf diarrheaUS3983228Nov 19, 1974Sep 28, 1976Merck & Co., Inc.Water-in-oil adjuvant compositionUS4016252Dec 11, 1975Apr 5, 1977Institut PasteurCalcium phosphate gel for adsorbing vaccinesUS4053587Jan 10, 1975Oct 11, 1977Research CorporationMethod of treating viral infectionsUS4069313Apr 7, 1976Jan 17, 1978Merck & Co., Inc.Water-in-oil adjuvant compositionUS4177263Dec 27, 1976Dec 4, 1979Research CorporationAnti-animal tumor methodUS4196185Jun 5, 1978Apr 1, 1980Hoffmann-La Roche Inc.Immunoassay for phencyclidineUS4197237Feb 12, 1975Apr 8, 1980Syva CompanyAntibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereofUS4197286Sep 27, 1977Apr 8, 1980Southwest Research InstituteTestosterone derivatives and assay methodUS4213964Dec 7, 1978Jul 22, 1980Miles Laboratories, Inc.Diphenylhydantoin antibodiesUS4215036Aug 15, 1978Jul 29, 1980Research CorporationModified grass pollen antigensUS4218436Apr 26, 1979Aug 19, 1980The Upjohn CompanyCompounds and methodsUS4329281Dec 21, 1979May 11, 1982Hoffmann-La Roche Inc.Hapten compositionsUS4330530Dec 22, 1980May 18, 1982The Procter & Gamble CompanyAnti-arthritic compositions and method using gold salts and organophosphonatesUS4332787Jun 23, 1980Jun 1, 1982The Massachusetts General HospitalAssay for beta-adrenergic antagonists and antibody thereforUS4339437Jul 26, 1979Jul 13, 1982Research CorporationAnti-tumor methodUS4346074Aug 16, 1979Aug 24, 1982National Research Development Corp.Pasteurellosis vaccinesUS4451570Mar 26, 1981May 29, 1984The Regents Of The University Of CaliforniaImmunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell lineUS4487780Feb 5, 1982Dec 11, 1984Scheinberg Israel HMethod of treatment of rheumatoid arthritisUS4578270Feb 22, 1984Mar 25, 1986Human Oltoanyagtermelo Es Kutato IntezetProcess for the preparation of lyophilized, adsorbed polyvalent vaccinesUS4594325Mar 26, 1981Jun 10, 1986The Regents Of The University Of Calif.High fusion frequency fusible lymphoblastoid cell lineUS4608252Sep 27, 1985Aug 26, 1986Syntex (U.S.A.) Inc.Chloramphenicol derivatives antigens and antibodiesUS4624921Apr 26, 1984Nov 25, 1986Cetus CorporationHuman lymphoblastold cell line and hybridomas derived therefromUS4624923Jan 24, 1986Nov 25, 1986Yeda Research And Development Company LimitedMetal-coated polyaldehyde microspheresUS4639336Jun 14, 1984Jan 27, 1987Roussel UclafNovel radioactive estradienes labelled with iodineUS4657763Sep 3, 1985Apr 14, 1987Michael EbertCombined chrysotherapeutic agents for autoimmune diseasesUS4693975Nov 20, 1984Sep 15, 1987The Wistar InstituteHuman hybridroma fusion partner for production of human monoclonal antibodiesUS4710378Mar 8, 1985Dec 1, 1987Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteLyophilized hepatitis B vaccineUS4720459Feb 14, 1985Jan 19, 1988Medical College Of Wisconsin Research Foundation, Inc.Myelomas for producing human/human hybridomasUS4740589Jul 11, 1986Apr 26, 1988Burroughs Wellcome Co.Capsular polysaccharide metal complex vaccinesUS4744760Jan 14, 1985May 17, 1988University Of British ColumbiaColloidal sized metal-polysaccharide particlesUS4753873Feb 3, 1986Jun 28, 1988Cambridge Bioscience CorporationPeptides for the diagnosis of HTLV-III antibodies, their preparation and useUS4812556May 18, 1987Mar 14, 1989VirovahlSynthetic peptide antigen for the detection of HIV-2 infectionUS4880750Jul 9, 1987Nov 14, 1989Miragen, Inc.Individual-specific antibody identification methodsUS4882423Mar 30, 1987Nov 21, 1989Calpis Food IndustrySubstance-conjugated complement component C1qUS4906564Mar 13, 1987Mar 6, 1990The United States Of America As Represented By The Secretary Of The ArmyAntigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigensUS4977286Sep 9, 1988Dec 11, 1990Trustees Of The University Of PennsylvaniaGlycolipidsUS5017687Jun 13, 1988May 21, 1991Virovahl, S.A.Peptides for the detection of HTLV-1 infectionUS5019497Jul 5, 1988May 28, 1991Lennart OlssonHuman squamous lung carcinoma cell specific antigens and antibodiesUS5035995May 22, 1989Jul 30, 1991Calpis Food Industry Co., Ltd.Test method involving substance-conjugated complement component C1qUS5047523Aug 2, 1988Sep 10, 1991Ortho Diagnostic Systems Inc.Nucleic acid probe for detection of neisseria gonorrhoeaUS5112606Sep 29, 1989May 12, 1992Sadao ShiosakaMethod of producing antibodies using colloidal metal as carrierUS5126253Sep 25, 1986Jun 30, 1992Suntory LimitedCell lines for use in the preparation of hybridoma cellsUS5169754Oct 31, 1990Dec 8, 1992Coulter CorporationBiodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making sameUS5242828Nov 9, 1989Sep 7, 1993Pharmacia Biosensor AbSensing surfaces capable of selective biomolecular interactions, to be used in biosensor systemsUS5248772Jan 29, 1992Sep 28, 1993Coulter CorporationFormation of colloidal metal dispersions using aminodextrans as reductants and protective agentsUS5264221May 22, 1992Nov 23, 1993Mitsubishi Kasei CorporationDrug-containing protein-bonded liposomeUS5294369Dec 5, 1990Mar 15, 1994Akzo N.V.Ligand gold bondingUS5376556Sep 11, 1992Dec 27, 1994Abbott LaboratoriesSurface-enhanced Raman spectroscopy immunoassayUS5384073Jan 21, 1994Jan 24, 1995Akzo N.V.Ligand gold bondingUS5434088May 24, 1994Jul 18, 1995Tosoh CorporationMethod of and kit for energy transfer immunoassay with colloidal particlesUS5436161Jul 22, 1994Jul 25, 1995Pharmacia Biosensor AbMatrix coating for sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systemsUS5446090Nov 12, 1993Aug 29, 1995Shearwater Polymers, Inc.Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and moleculesUS5466609Oct 29, 1992Nov 14, 1995Coulter CorporationBiodegradable gelatin-aminodextran particle coatings of and processes for making sameUS5498421Feb 22, 1994Mar 12, 1996Vivorx Pharmaceuticals, Inc.Composition useful for in vivo delivery of biologics and methods employing sameUS5521289Jul 29, 1994May 28, 1996Nanoprobes, Inc.Small organometallic probesUS5639725Apr 26, 1994Jun 17, 1997Children's Hospital Medical Center Corp.Angiostatin proteinUS5686578Aug 5, 1994Nov 11, 1997Immunomedics, Inc.Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotypeUS5736410Jun 7, 1995Apr 7, 1998Sri InternationalUp-converting reporters for biological and other assays using laser excitation techniquesUS5874226May 22, 1995Feb 23, 1999H. Lee BrowneIn situ immunodetection of antigensUS5972720Jun 5, 1997Oct 26, 1999Roche Diagnostics GmbhStabilization of metal conjugatesUS6274552Nov 10, 1997Aug 14, 2001Cytimmune Sciences, Inc.Composition and method for delivery of biologically-active factorsUS6407218Nov 10, 1998Jun 18, 2002Cytimmune Sciences, Inc.Method and compositions for enhancing immune response and for the production of in vitro mabsUS6447765Mar 3, 1999Sep 10, 2002University Of Southern CaliforniaUse of cytokines and mitogens to inhibit graft versus host diseaseUS6528051Aug 22, 2001Mar 4, 2003Cytimmune Sciences, Inc.Methods and compositions for enhancing immune responseUS6528485Jun 5, 2000Mar 4, 2003Applied Research Systems Ars Holding N.V.Site-specific preparation of polyethylene glycol-grf conjugatesUS6530944Feb 8, 2001Mar 11, 2003Rice UniversityOptically-active nanoparticles for use in therapeutic and diagnostic methodsUS6593292Aug 24, 2000Jul 15, 2003Cellgate, Inc.Compositions and methods for enhancing drug delivery across and into epithelial tissuesUS6624886May 13, 2002Sep 23, 2003Surromed, Inc.SERS substrates formed by hydroxylamine seeding of colloidal metal nanoparticle monolayersUS6734168May 7, 2001May 11, 2004The Trustees Of Columbia University In The City Of New YorkEndothelial monocyte activating polypeptide II: a mediator which activates host responseUS6821529Sep 5, 2001Nov 23, 2004Deanna Jean NelsonOligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayersUS6869932Nov 20, 2002Mar 22, 2005Applied Research Systems Ars Holding N.V.Site-specific preparation of polyethlene glycol-GRF conjugatesUS7229841Mar 8, 2002Jun 12, 2007Cytimmune Sciences, Inc.Colloidal metal compositions and methodsUS7387900Apr 30, 2002Jun 17, 2008Cytimmune Sciences, Inc.Colloidal metal compositions and methodsUS7547438Dec 20, 2006Jun 16, 2009Pangenetics BvCD40-binding activating antibodiesUS20010055581Mar 9, 2001Dec 27, 2001Lawrence TamarkinComposition and method for delivery of biologically-active factorsUS20020071826Aug 22, 2001Jun 13, 2002Lawrence TamarkinMethods and compositions for enhancing immune response and for the production of in vitro MabsUS20030053983Apr 30, 2002Mar 20, 2003Lawrence TamarkinColloidal metal compositions and methodsUS20030180252Dec 19, 2002Sep 25, 2003Lawrence TamarkinMethods and compositions for enhancing immune response and for the production of in vitro MabsUS20030235908 *Jan 22, 2003Dec 25, 2003Xcyte Therapies, Inc.Activation and expansion of cellsUS20040018203Jun 8, 2001Jan 29, 2004Ira PastanPegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugatesUS20040029794Nov 20, 2002Feb 12, 2004Applied Research Systems Ars Holding N.V.Site-specific preparation of polyethlene glycol-GRF conjugatesUS20040054139Jun 22, 2001Mar 18, 2004Mark PageModification of hepatitis b core antigenUS20040204576Jul 2, 2003Oct 14, 2004Donald JacksonPolynucleotides encoding a novel human phosphatase, BMY_HPP13US20040213760Sep 26, 2003Oct 28, 2004Lawrence TamarkinComposition and method for delivery of biologically-active factorsUS20050003431Jul 21, 2004Jan 6, 2005Wucherpfennig Kai W.Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses thereforUS20050085513Oct 14, 2004Apr 21, 2005Immunogen Inc.Cytotoxic agents containing novel potent taxanes and their therapeutic useUS20070014798Sep 22, 2006Jan 18, 2007Ernst Peter RieberAntibodies to dendritc cells and human dendritic cell populations and uses thereofUS20070160572Sep 6, 2006Jul 12, 2007Lawrence TamarkinColloidal metal compositions and methodsUS20070231408May 22, 2007Oct 4, 2007Lawrence TamarkinColloidal metal compositions and methods* Cited by examinerNon-Patent CitationsReference1Australian Office Action-Application No. 2004311630, Australian Office Action, pp. 1-4, Oct. 9, 2009.2Australian Office Action�Application No. 2004311630, Australian Office Action, pp. 1-4, Oct. 9, 2009.3Balkwill et al., The Cytokine Network, Immunology Today, vol./Iss: 10(9), pp. 299-304, Jan. 1, 1989.4Baron, S., Figure: Genetic Map of Adenovirus Type 2, Medical Microbiology, vol./Iss: 4th Ed., pp. Fig. 67-3, Jan. 1, 1996.5Borrebaeck et al., Human Monoclonal Antibodies Produced by Primary in Vitro Immunization of Peripheral Blood Lymphocytes, Proceedings of the National Academy of Science USA, vol./Iss: 85, pp. 3995-3999, Jun. 1, 1986.6Brust et al., Novel Gold-Dithiol Nano-Networks with Non-Metallic Electronic Properties, Advanced Materials, vol./Iss: 7 (9), pp. 795-797, Jan. 1, 1995.7Calabresi et al., Chemotherapy of Neoplastic Diseases, Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol./Iss: 9th Edition, pp. 1260-1261, 1293, Jan. 1, 1996.8Calabresi et al.,Chemotherapy of Neoplastic Diseases, Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol./Iss: 9th Edition, pp. 1225-1232, Jan. 1, 1996.9Canadian Office Action-2,309,604, Canadian Office Action, pp. 1-2, Feb. 11, 2008.10Canadian Office Action�2,309,604, Canadian Office Action, pp. 1-2, Feb. 11, 2008.11Canadian Office Action-2,309,604, Canadian Office Action, pp. 1-4, May 18, 2006.12Canadian Office Action�2,309,604, Canadian Office Action, pp. 1-4, May 18, 2006.13Ciesiolka et al., An 8- to 10-fold Enhancement in Sensitivity for Quantitation of Proteins by Modified Application of Colloidal Gold, Analytical Biochemistry, vol./Iss: 168 (2) pp. 280-283, Feb. 1, 1988.14Coulombe et al., Cytochemical Demonstration of Increased Phospholipid Content in Cell Membranes in Chlorphentermine-Induced Phospholipidosis, Journal of Histochemistry and Cytochemistry, vol./Iss: 37 (2), pp. 139-147, Jan. 1, 1989.15De Brabander et al., Probing Microtubule-Dependent Intracellular Motility with Nanometer Particle Video Ultramicroscopy (nanovid ultramicroscopy) (Abstract Only), Cytobios, vol./Iss: 43, pp. 273-283, Jan. 1, 1985.16De Roe et al., A Model of Protein-Colloidal Gold Interactions, The Journal of Histochemistry and Cytochemistry, vol./Iss: 35 (11), pp. 1191-1198, Jan. 1, 1987.17De Roe et al., A Model of Protein�Colloidal Gold Interactions, The Journal of Histochemistry and Cytochemistry, vol./Iss: 35 (11), pp. 1191-1198, Jan. 1, 1987.18Deng et al., Self-Assembled Monolayers of Alkanethiolates Presenting Tri(propylene sulfoxide) Groups Resist the Adsorption of Protein, Journal of the American Chemical Society, vol./Iss: 118 (19), pp. 5136-5137, May 15, 1996.19Dominguez et al., Effect of Heart Treatment on the Antigen-Binding Activity of Anti-Peroxidase Immunoglobulins in Bovine Colostrum, Journal of Dairy Science, vol./Iss: 80 (12), pp. 3182-3187, Dec. 1, 1998.20 *Dynabeads product information, 2010, pp. 1-3.21Elliott et al., Analysis of Colloidal Gold Probes by Isoelectric Focusing in Agarose Gels, Analytical Biochemistry, vol./Iss: 186 (1), pp. 53-59, Apr. 1, 1990.22EPO Search Report, EPO Application 04821049.6 Search Report, EPO Search Report, pp. 1-10, Oct. 19, 2009.23EPO Search Report-98957757.2, EPO Search Report, pp. 1-3, Oct. 31, 2003.24EPO Search Report�98957757.2, EPO Search Report, pp. 1-3, Oct. 31, 2003.25EPO Search Report-98957757.2, EPO Search Report, pp. 1-4, Aug. 2, 2004.26EPO Search Report�98957757.2, EPO Search Report, pp. 1-4, Aug. 2, 2004.27EPO Searching Authority, Search Report EPO-Application No. 02729092.3, EPO Search Report, pp. 1-6, Jul. 13, 2009.28EPO Searching Authority, Search Report EPO�Application No. 02729092.3, EPO Search Report, pp. 1-6, Jul. 13, 2009.29FDA Updates, FDA Consumer, vol./Iss: 33 (6), pp. 5, Nov. 1, 1999.30Fitzgerald et al., Adenovirus-Induced Release of Epidermal Growth Factor and Pseudomonas Toxin into the Cytosol of KB Cells during Receptor-Mediated Endocytosis, Cell, vol./Iss: 32, pp. 607-617, Feb. 1, 1983.31Fraker et al., Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity, The Journal of Experimental Medicine, vol./Iss: 170, pp. 1015-1020, Jan. 1, 1989.32Gallego et al., Ultrastructural Identification of the Splenic Follicular Dendritic Cells in the Chicken, The Anatomical Record, vol./Iss: 242, pp. 220-224, Jan. 1, 1995.33Goldstein et al., Cardiovascular Effects of Platelet-Activating Factor, Lipids, vol./Iss: 26(212), pp. 1250-1256, Jan. 1, 1991.34Grainger et al, Polymeric Monolayers on Solid Substrates by Spontaneous Adsorption from Solution, American Chemical Society-Abstracts of Papers, vol./Iss: Part 1, pp. Paragraph 074, Aug. 20, 1995.35Grainger et al, Polymeric Monolayers on Solid Substrates by Spontaneous Adsorption from Solution, American Chemical Society�Abstracts of Papers, vol./Iss: Part 1, pp. Paragraph 074, Aug. 20, 1995.36Gref et al., The Controlled Intravenous Delivery of Drugs using PEG-Coated Sterically Stabilized Nanospheres, Advanced Drug Delivery Reviews, vol./Iss: 16, pp. 215-233, Jan. 1, 1995.37Hashimoto et al., Action Site of Circulating Interleukin-1 on the Rabbit Brain, Brain Research, vol./Iss: 540, pp. 217-223, Jan. 1, 1991.38Hisamatsu et al., Platelet Activating Factor Induced Respiratory Mucosal Damage, Lipids, vol./Iss: 26 (12), pp. 1287-1291, Jan. 1, 1991.39Hopkins et al., Early Events Following the Binding of Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells, European Journal of Cell Biology, vol./Iss: 24, pp. 259-264, Jan. 1, 1981.40Ito et al., Antitumor Reactivity of Anti-CD3/Anti-CD28 Bead-Activated Lymphoid Cells: Implications for Cell Therapy in a Murine Model, Journal of Immunotherapy, vol./Iss: 26 (3), pp. 222-233, Jan. 1, 2003.41Japanese Office Action cited in 2000-520162 (with English translation), Japanese Office Action, pp. 1-3, Jun. 4, 2010.42Japanese Office Action cited in 2000-520162 (with English translation), Japanese Office Action, pp. 1-3, Oct. 22, 2009.43Japanese Office Action cited in 2000-520162 (with English translation), Japanese Office Action, pp. 1-7, Apr. 14, 2009.44Japanese Patent Office, Japanese Patent Application 2000-520153 Office Action as translated by Foreign Associate, Japanese Office Action, pp. 1-10, Oct. 6, 2009.45Japanese Publication, Japanese Laid-Open Publication No. 9-107980 English Abstract only-of Japanese Patent Application 08-231415, pp. 1-3, Apr. 28, 1997.46Japanese Publication, Japanese Laid-Open Publication No. 9-107980 English Abstract only�of Japanese Patent Application 08-231415, pp. 1-3, Apr. 28, 1997.47Kang et al., Ultrastructural and Immunocytochemical Study of the Uptake and Distribution of Bacterial Lipopolysaccaride in Human Monocytes, Journal of Leukemia Biology, vol./Iss: 48, pp. 316-332, Jan. 1, 1990.48Kimball, Chapter 7-B Lymphocytes, Introduction to Immunology, pp. 184-190, Jan. 1, 1990.49Kimball, Chapter 7�B Lymphocytes, Introduction to Immunology, pp. 184-190, Jan. 1, 1990.50Kirchner et al., The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2, Cancer, vol./Iss: 67 (7), pp. 1862-1864, Apr. 1, 1991.51Koganty, R.R., Vaccine Safety: A Case for Synthetic Vaccine Formulations, Expert Review of Vaccines, vol./Iss: 2 (6), pp. 725-727, Dec. 1, 2003.52Koning, et al., Selective Transfer of a Lipophilic Prodrug of 5-Fluorodeoxyuridine from Immunoliposomes to Colon Cancer Cells, Biochimica et Biphysica Acta, vol./Iss: 1420, pp. 153-167, Jun. 2, 1999.53Lang et al., A New Class of Thiolipids for the Attachment of Lipid Bilayers on Gold Surfaces, Langmuir, vol./Iss: 10 (1), pp. 197-210, Jan. 1, 1994.54Lanzavecchia, Identifying Strategies for Immune Interventor, Science, vol./Iss: 260, pp. 937-944, Jan. 1, 1993.55Lemmon et al., Preparation and Characterization of Nanocomposites of Poly(ethylene oxide) with Layered Solids, New Techniques and Approaches, vol./Iss: Chapter 5, pp. 43-54, Jan. 1, 1995.56Leuvering et al., A Sol Particle Agglutination Assay for Human Chorionic Gonadotrophin, Journal of Immunological Methods, vol./Iss: 45 (2), pp. 183-194, Jan. 1, 1981.57Lezzi et al., Chelating Resins Supporting Dithiocarbamate and Methylthiourea Groups in Adsorption of Heavy Metal Ions, Journal of Applied Polymer Science, vol./Iss: 54 (7), pp. 889-897, Nov. 14, 1994.58Lezzi et al., Synthesis of Thiol Chelating Resins and Their Adsorption Properties toward Heavy Metal Ions, Journal of Polymer Science, vol./Iss: 32, pp. 1877-1883, Jan. 1, 1994.59 *Li et al., 2000, Colloids and surfaces, vol. 175: 217-223.60Li et al., Plasma Protein Interactions with Copolymer-Stabilized Colloids, Dissertation Abstracts International, vol./Iss: 54 (7), pp. 3735-B, Jan. 1, 1994.61Magez et al., Specific Uptake of Tumor Necrosis Factor-a is Involved in Growth Control of Trypanosoma brucei, The Journal of Cell Biology, vol./Iss: 137 (3), pp. 715-727, May 5, 1997.62Mathias et al., Sulfur-Substituted Polyoxyethylenes Sequential Ether-Thioether Copolymers, Crown Ethers and Phase Transfer Catalysis in Polymer Science, pp. 359-370, Jan. 1, 1984.63Morris et al., Validation of the Biotinyl Ligand-Avidin-Gold Technique, Cytochemistry, vol./Iss: 40, pp. 711-721, Jan. 1, 1992.64Mrksich et al., Surface Plasmon Resonance Permits in Situ Measurement of Protein Adsorption on Self-Assembled Monolayers of Alkanethiolates on Gold, Langmuir, vol./Iss: 11, pp. 4383-4385, Jan. 1, 1995.65Nakashima et al., Electrochemical Characterization of an Assembled Monolayer of alpha-Methoxy-omega-mercapto-poly(ethylene glycol) on Gold and Complex Formation of the Monolayer with alpha-Cyclodextrin, Chemistry Letters, pp. 731-732, Jan. 1, 1996.66Nakashima et al., Electrochemical Characterization of an Assembled Monolayer of α-Methoxy-ω-mercapto-poly(ethylene glycol) on Gold and Complex Formation of the Monolayer with α-Cyclodextrin, Chemistry Letters, pp. 731-732, Jan. 1, 1996.67Niwa et al., Two-Dimensional Array of Poly(methacrylic acid) Brushes on Gold Substrates. Interaction with Ferrocen-Terminated Poly(oxyethylene)s, Macromolecules, vol./Iss: 28 (23), pp. 7770-7774, Nov. 6, 1995.68Office Action-Peoples Republic of China-Application No. 200480041234.5, Peoples Republic of China-Office Action, pp. 1-18, Jun. 27, 2008.69Office Action�Peoples Republic of China�Application No. 200480041234.5, Peoples Republic of China�Office Action, pp. 1-18, Jun. 27, 2008.70Ohmann et al., Expression of Tumor Necrosis Factor-alpha Receptors on Bovine Macrophges. Lymphocytes and Polymorphonuclear Luekocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects, Lymphokine Research, vol./Iss: 9 (1), pp. 43-58, Jan. 1, 1990.71Ohmann et al., Expression of Tumor Necrosis Factor-α Receptors on Bovine Macrophges. Lymphocytes and Polymorphonuclear Luekocytes, Internalization of Receptor-Bound Ligand, and Some Functional Effects, Lymphokine Research, vol./Iss: 9 (1), pp. 43-58, Jan. 1, 1990.72Otsuka et al., Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with alpha-Lactosyl-omega-mercapto-poly(ethylene glycol), Journal of the American Chemical Society, vol./Iss: 123, pp. 8226-8230, Feb. 20, 2001.73Otsuka et al., Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with α-Lactosyl-ω-mercapto-poly(ethylene glycol), Journal of the American Chemical Society, vol./Iss: 123, pp. 8226-8230, Feb. 20, 2001.74Paciotti et al., (XP-001537146) #3858-Comparison of the Toxicity and Pharmacokinetics of Neat and Colloidal Gold Boung TNF, Proceedings of the American Association for Cancer Research, vol./Iss: 40, pp. 585, Mar. 1, 1999.75Paciotti et al., (XP-001537146) #3858�Comparison of the Toxicity and Pharmacokinetics of Neat and Colloidal Gold Boung TNF, Proceedings of the American Association for Cancer Research, vol./Iss: 40, pp. 585, Mar. 1, 1999.76Paciotti et al., (XP-001537149) #1048-The Use of Colloidal Gold in Cytokine Immununotherapy, Proceedings of the American Association for Cancer Research, vol./Iss: 39, pp. 153, Mar. 1, 1998.77Paciotti et al., (XP-001537149) #1048�The Use of Colloidal Gold in Cytokine Immununotherapy, Proceedings of the American Association for Cancer Research, vol./Iss: 39, pp. 153, Mar. 1, 1998.78Paciotti et al., Interleukin 1 Directly Regulates Hormone-Dependent Human Breast Cancer Cell Proliferation in Vitro, Molecular Endocrinology, vol./Iss: 2, pp. 459-464, Jan. 1, 1988.79Paciotti et al., Interleukin 1alpha Differentially Synchronizes Estrogen Dependent and Estrogen-Independent Human Breast Cells in Gg/G1 Phase of the Cell Cycle, Anti-Cancer Research, vol./Iss: 11, pp. 25-32, Jan. 1, 1991.80Paciotti et al., Interleukin 1α Differentially Synchronizes Estrogen Dependent and Estrogen-Independent Human Breast Cells in Gg/G1 Phase of the Cell Cycle, Anti-Cancer Research, vol./Iss: 11, pp. 25-32, Jan. 1, 1991.81Paciotti et al., Interleukin 2 Differentially Effects the Proliferation of a Hormone-Dependent and a Hormone-Independent Human Breast Cancer Cell Line in Vitro and in Vivo, Anti-Cancer Research, vol./Iss: 8, pp. 1233-1240, Jan. 1, 1988.82PCT International Search Report cited in PCT/US04/40785, PCT International Search Report, pp. 1-2, Oct. 25, 2005.83PCT International Search Report cited in PCT/US08/82984, PCT International Search Report, pp. 1-4, Feb. 3, 2009.84Peters et al., Binding and Internalization of Biotinylated Interleukin-2 in Human Lymphocytes, Blood, vol./Iss: 76, pp. 97-104, Jan. 1, 1990.85Prakken et al., Artificial Antigen-Presenting Cells as a Tool to Exploit the Immune �Synapse�, Nature Medicine, vol./Iss: 6 (12), pp. 1406-1410, Dec. 1, 2000.86Prakken et al., Artificial Antigen-Presenting Cells as a Tool to Exploit the Immune 'Synapse', Nature Medicine, vol./Iss: 6 (12), pp. 1406-1410, Dec. 1, 2000.87Prime et al., Adsorption of Proteins onto Surfaces Containing End-Attached Oligo(ethylene oxide): A Model System Using Self-Assembled Monolayers, Journal of the American Chemical Society, vol./Iss: 115, pp. 10714-10721, Jan. 1, 1993.88Rabolt, J.F., Design and Construction of Two Component Heterogenous Polymer Surfaces by Self Assembly, Polymer Preprints, vol./Iss: 36 (1), pp. 84, Apr. 1, 1995.89Roitt et al., The Cytokine Network, Immunology, vol./Iss: 3rd ed., pp. 8-15, Jan. 1, 1993.90Stolnik et al., The Effects of Surface Coverage and Conformation of Poly(ethylene oxide) (PEO) Chains of Poloxamer 407 on the Biological Fate of Model Colloidal Drug Carriers, Biochimica et Biphysica Acta, vol./Iss: 1514, pp. 261-279, Oct. 1, 2001.91Thompson et al., A Phase I Trial of CD3/CD28-Activated T Cells (Xcellerated T Cells) and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma, Clinical Cancer Research, vol./Iss: 9, pp. 3562-3570, Sep. 1, 2003.92Tomii et al., Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Carrier, Japanes Journal of Medical Science and Biology, vol./Iss: 44, pp. 75-80, Jan. 1, 1991.93U.S. PTO Office Action cited in U.S. Appl. No. 12/267,847, U.S. PTO Office Action, pp. 1-11, Oct. 5, 2010.94USPTO Office Action cited in U.S. Appl. No. 10/672,144, U.S. PTO Office Action, pp. 1-5, Nov. 15, 2010.95USPTO Office Action-cite in U.S. Appl. No. 09/189,657, USPTO Office Action, pp. 1-15, Apr. 11, 2008.96USPTO Office Action�cite in U.S. Appl. No. 09/189,657, USPTO Office Action, pp. 1-15, Apr. 11, 2008.97USPTO Office Action-cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 108, Oct. 17, 2007.98USPTO Office Action�cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 108, Oct. 17, 2007.99USPTO Office Action-cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 1-10, Apr. 15, 2009.100USPTO Office Action�cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 1-10, Apr. 15, 2009.101USPTO Office Action-cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 1-6, Aug. 5, 2010.102USPTO Office Action�cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 1-6, Aug. 5, 2010.103USPTO Office Action-cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 1-8, Jan. 20, 2010.104USPTO Office Action�cited in U.S. Appl. No. 10/672,144, USPTO Office Action, pp. 1-8, Jan. 20, 2010.105USPTO Office Action-cited in U.S. Appl. No. 11/046,204, USPTO Office Action, pp. 1-20, Oct. 16, 2008.106USPTO Office Action�cited in U.S. Appl. No. 11/046,204, USPTO Office Action, pp. 1-20, Oct. 16, 2008.107USPTO Office Action-cited in U.S. Appl. No. 11/516,175, USPTO Office Action, pp. 1-9, Jun. 5, 2009.108USPTO Office Action�cited in U.S. Appl. No. 11/516,175, USPTO Office Action, pp. 1-9, Jun. 5, 2009.109USPTO Office Action-cited in U.S. Appl. No. 12/250,126, USPTO Office Action, pp. 1-12, Jun. 7, 2010.110USPTO Office Action�cited in U.S. Appl. No. 12/250,126, USPTO Office Action, pp. 1-12, Jun. 7, 2010.111USPTO Office Action-cited in U.S. Appl. No. 12/267,847, USPTO Office Action, pp. 1-11, Mar. 18, 2010.112USPTO Office Action�cited in U.S. Appl. No. 12/267,847, USPTO Office Action, pp. 1-11, Mar. 18, 2010.113USPTO Office Action-U.S. Appl. No. 11/004,623, USPTO Office Action, pp. 1-12, Aug. 5, 2008.114USPTO Office Action�U.S. Appl. No. 11/004,623, USPTO Office Action, pp. 1-12, Aug. 5, 2008.115USPTO Office Action-U.S. Appl. No. 11/004,623, USPTO Office Action, pp. 1-16, Nov. 6, 2007.116USPTO Office Action�U.S. Appl. No. 11/004,623, USPTO Office Action, pp. 1-16, Nov. 6, 2007.117USPTO Office Action-U.S. Appl. No. 11/004,623, USPTO Office Action, pp. 1-22, Feb. 22, 2007.118USPTO Office Action�U.S. Appl. No. 11/004,623, USPTO Office Action, pp. 1-22, Feb. 22, 2007.119Van Den Pol, A. N., Colloidal Gold and Biotin-Avidin Conjugates as Ultrastructural Markers for Neural Antigens, Quarterly Journal of Experimental Physiology, vol. 69, pp. 1-33, Jan. 1, 1984.120Van Rensen et al., Liposomes with Incorporated MHC Class II/Peptide Complexes as Antigen Presenting Vesicles for Specific T Cell Activation, Pharmaceutical Research, vol./Iss: 16 (2), pp. 198-204, Jan. 1, 1999.121Vidal et al., Steric Stabilization of Polystyrene Colloids Using Thiol-ended Polyethylene Oxide, Polymers for Advanced Technologies, vol./Iss: 6, pp. 473-479, Nov. 15, 1994.122Walden et al., Induction of Regulatory T-lymphocyte Responses by Liposomes Carrying Major Histocompatibility Complex Molecules and Foreign Antigen, Nature, vol./Iss: 315, pp. 327-329, May 23, 1985.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS20120134956 *Oct 26, 2011May 31, 2012Cytimmune Sciences, Inc.Colloidal metal compositions and methods* Cited by examinerClassifications U.S. Classification436/525, 530/811, 424/278.1International ClassificationC07K16/24, A61K31/28, A01N55/02, A61K45/00, A61K47/00, A61K39/395, G01N33/553, A61K47/48, A61K48/00, A61K9/14, A61K38/16Cooperative ClassificationY10S530/811, A61K47/48861, A61K47/48884, A61K47/4833, B82Y5/00, A61K33/38, A61K31/28, A61K33/26, A61K45/06, A61K33/06, C07K16/241, A61K33/24European ClassificationA61K47/48R6D, C07K16/24B, A61K33/38, B82Y5/00, A61K33/26, A61K33/24, A61K45/06, A61K47/48W8B, A61K31/28, A61K33/06, A61K47/48W14BLegal EventsDateCodeEventDescriptionDec 16, 2009ASAssignmentOwner name: CYTIMMUNE SCIENCES, INC.,MARYLANDFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, LAWRENCE;PACIOTTI, GIULIO F.;US-ASSIGNMENT DATABASE UPDATED:20100318;REEL/FRAME:23662/231Effective date: 20050128Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, LAWRENCE;PACIOTTI, GIULIO F.;REEL/FRAME:023662/0231Owner name: CYTIMMUNE SCIENCES, INC., MARYLANDRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google